Scanbo

Scanbo is an AI-driven medtech company that has developed a non-invasive device for monitoring blood glucose levels and blood pressure. The company's prototype combines a three-lead ECG measurement and a photoplethysmogram (PPG) to capture data for 60 seconds. This data is then analyzed using machine learning algorithms, including convolutional neural networks and deep neural networks, to provide accurate readings for blood glucose and blood pressure levels.

Scanbo's device represents a significant advancement in diabetes management, as it eliminates the need for painful finger pricks and the use of disposable test strips. The company claims that its technology can achieve accuracy levels within a couple of percentage points compared to conventional finger-prick glucose monitors. Additionally, Scanbo's device can perform cuff-less blood pressure measurements by analyzing ECG data and calculating short-wave transmission lengths.

The company is positioning its technology as a cost-effective and environmentally friendly alternative to existing clinical techniques and devices. According to Scanbo's CEO, Ashissh Raichura, the device could potentially cost as low as USD 20 per month for users, without the need for any disposables or bio-waste. This approach could make blood glucose monitoring more accessible to the estimated 400 million people worldwide with type two diabetes, many of whom cannot afford traditional glucometers or continuous glucose monitors.

Scanbo is currently in the process of seeking regulatory approvals, including from the US FDA and Health Canada, to bring its products to market. The company has filed two patents related to the hardware design and sensor integration of its device.